Research ArticleCELL THERAPY

Lymph node fibroblastic reticular cell transplants show robust therapeutic efficacy in high-mortality murine sepsis

Science Translational Medicine  13 Aug 2014:
Vol. 6, Issue 249, pp. 249ra109
DOI: 10.1126/scitranslmed.3009377

You are currently viewing the editor's summary.

View Full Text
As a service to the community, AAAS/Science has made this article free with registration.

A Swiss Army Knife for Treating Sepsis

Sepsis is a complication of infection that kills ~7 million people a year, with no successful molecular therapy thus far. But cells are more versatile than molecules: They make products and respond to their environments. Now, Fletcher et al. investigate whether these multifunctional tools are better equipped to battle this multifocal disease. They showed that one injection of anti-inflammatory cells derived from the lymph nodes dramatically increased survival in two mouse models of sepsis, even when delivered late in the disease course and under conditions that mimic those in the clinic. These beneficial cells reduced the deadly sepsis-associated “cytokine storm” by dampening this response in a manner that required the induction of nitric oxide synthase 2.